Granted Patent
B2
US 12,351,578 · App. 17/974,342 · Granted Jul 8, 2025
Compounds for inhibiting NLRP3 and uses thereof
Assignee:
Ventus Therapeutics U.S., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
Claims (31)
1. A method of treating a disease, condition, or disorder comprising administering to a human subject in need thereof a compound of Formula (II-h):
or a pharmaceutically acceptable salt thereof;
wherein:
R 1 is
Y is phenyl independently substituted with one, two, or three substituents selected from the group consisting of C 1 -C 6 haloalkyl, halo, and —R 4 OR 5 ;
R 2a is hydrogen;
R 4 is a bond; and
R 5 is hydrogen;
wherein treating is alleviation of an established symptom of said disease, condition or disorder in said human subject, and
wherein said disease, condition or disorder is selected from the group consisting of a liver disease, a kidney disease, and a cardiovascular disease.
2. The method according to claim 1 , wherein the disease, condition or disorder is a liver disease.
3. The method according to claim 1 , wherein the disease, condition or disorder is a kidney disease.
4. The method according to claim 1 , wherein the disease, condition or disorder is a cardiovascular disease.
5. The method according to claim 1 , wherein R 1 is
6. The method according to claim 5 , wherein Y is phenyl independently substituted with one substituent selected from the group consisting of halo and —R 4 OR 5 .
7. The method according to claim 5 , wherein Y is phenyl independently substituted with two substituents selected from the group consisting of halo and —R 4 OR 5 .
8. The method according to claim 7 , wherein one of the two substituents is halo and the other substituent is —R 4 OR 5 .
9. The method according to claim 8 , wherein the halo is chloro.
10. The method according to claim 9 , wherein the disease, condition or disorder is a liver disease.
11. The method according to claim to 9 , wherein the disease, condition or disorder is a kidney disease.
12. The method according to claim 9 , wherein the disease, condition or disorder is a cardiovascular disease.
13. The method according to claim 1 , wherein Y is phenyl substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 6 haloalkyl, halo, and —R 4 OR 5 ; wherein one substituent is halo.
14. The method according to claim 13 , wherein the one substituent is chloro.
15. The method according to claim 14 , wherein Y is phenyl further substituted with —R 4 OR 5 .
16. The method according to claim 5 , wherein Y is phenyl substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 6 haloalkyl, halo, and —R 4 OR 5 ; wherein one substituent is halo.
17. The method according to claim 16 , wherein the one substituent is chloro.
18. The method according to claim 17 , wherein Y is phenyl further substituted with —R 4 OR 5 .
19. The method according to claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.
20. The method according to claim 19 , wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2023
From: DORICH, STÉPHANE; CHEFSON, AMANDINE; CÔTÉ, ALEXANDRE
To: VENTUS THERAPEUTICS, INC.
Reel/Frame 065136/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2023
From: BURCH, JASON; ST-ONGE, MIGUEL
To: VENTUS THERAPEUTICS, INC.
Reel/Frame 065136/0919 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2023
From: VENTUS THERAPEUTICS, INC.
To: VENTUS THERAPEUTICS U.S., INC.
Reel/Frame 065136/0931 →
Continuity (4)
Continuation
17528928
· Nov 17, 2021
Provisional Application
63171932
· Apr 7, 2021
References Cited (400)
US 3753988A
· Rodway et al.
· 1973
[cited by applicant]
US 4522811A
· Eppstein et al.
· 1985
[cited by applicant]
US 5089494A
· Iwase et al.
· 1992
[cited by applicant]
US 5324727A
· Iwase et al.
· 1994
[cited by applicant]
US 5565472A
· Hamanaka
· 1996
[cited by applicant]
US 5621027A
· Roschger et al.
· 1997
[cited by applicant]
US 5763263A
· Dehlinger
· 1998
[cited by applicant]
US 5849741A
· Watanabe et al.
· 1998
[cited by applicant]
US 6114530A
· Yuan et al.
· 2000
[cited by applicant]
US 6218392B1
· Watanabe et al.
· 2001
[cited by applicant]
US 6288064B1
· Watanabe et al.
· 2001
[cited by applicant]
US 6316438B1
· Yu et al.
· 2001
[cited by applicant]
US 6353103B1
· Yuan et al.
· 2002
[cited by applicant]
US 6486158B1
· Wang et al.
· 2002
[cited by applicant]
US 6858624B2
· Hagen et al.
· 2005
[cited by applicant]
US 7087621B2
· Sang et al.
· 2006
[cited by applicant]
US 7560551B2
· Cee et al.
· 2009
[cited by applicant]
US 7666898B2
· Chang et al.
· 2010
[cited by applicant]
US 7790882B2
· Carreira
· 2010
[cited by applicant]
US 8067608B2
· Beachy et al.
· 2011
[cited by applicant]
US 8106066B2
· Schumacher et al.
· 2012
[cited by applicant]
US 8318793B2
· Turner et al.
· 2012
[cited by applicant]
US 8329698B2
· Cravo et al.
· 2012
[cited by applicant]
US 8338591B2
· Yoon et al.
· 2012
[cited by applicant]
US 8445473B2
· Wang et al.
· 2013
[cited by applicant]
US 8575183B2
· Cushing et al.
· 2013
[cited by applicant]
US 8642660B2
· Goldfarb
· 2014
[cited by applicant]
US 8658801B2
· Loiseleur et al.
· 2014
[cited by applicant]
US 8674097B2
· Cravo et al.
· 2014
[cited by applicant]
US 8791113B2
· Dorsch et al.
· 2014
[cited by applicant]
US 8846673B2
· Duan et al.
· 2014
[cited by applicant]
US 8895587B2
· Cassayre et al.
· 2014
[cited by applicant]
US 8912202B2
· Staehle et al.
· 2014
[cited by applicant]
US 8932557B2
· Chen et al.
· 2015
[cited by applicant]
US 8940724B2
· Cushing et al.
· 2015
[cited by applicant]
US 8980929B2
· Hicks et al.
· 2015
[cited by applicant]
US 8981087B2
· Shuttleworth et al.
· 2015
[cited by applicant]
US 9023490B2
· Che
· 2015
[cited by applicant]
US 9198907B2
· Lahser et al.
· 2015
[cited by applicant]
US 9266855B2
· Turner et al.
· 2016
[cited by applicant]
US 9309231B2
· Zhang et al.
· 2016
[cited by applicant]
US 9458168B2
· Trzupek et al.
· 2016
[cited by applicant]
US 9481672B2
· Fürstner et al.
· 2016
[cited by applicant]
US 9593108B2
· Maccoss et al.
· 2017
[cited by applicant]
US 9598417B2
· Haßfeld et al.
· 2017
[cited by applicant]
US 9617279B1
· Zhang
· 2017
[cited by applicant]
US 9675073B2
· Rawal et al.
· 2017
[cited by applicant]
US 9765039B2
· Fairfax et al.
· 2017
[cited by applicant]
US 9879022B2
· Trzupek et al.
· 2018
[cited by applicant]
US 9949977B2
· Fürstner et al.
· 2018
[cited by applicant]
US 9949978B2
· Fürstner et al.
· 2018
[cited by applicant]
US 20030124053A1
· Barrett et al.
· 2003
[cited by applicant]
US 20040242886A1
· Gupta et al.
· 2004
[cited by applicant]
US 20060156485A1
· Lim
· 2006
[cited by applicant]
US 20060276505A1
· Nelson et al.
· 2006
[cited by applicant]
US 20070179123A1
· Chiang et al.
· 2007
[cited by applicant]
US 20090082358A1
· Nishimura et al.
· 2009
[cited by applicant]
US 20090105266A1
· Glatthar et al.
· 2009
[cited by applicant]
US 20090124624A1
· Augereau et al.
· 2009
[cited by applicant]
US 20090239896A1
· Chang et al.
· 2009
[cited by applicant]
US 20090318476A1
· Ramtohul
· 2009
[cited by applicant]
US 20110124661A1
· Brnardic et al.
· 2011
[cited by applicant]
US 20110150833A1
· Feng et al.
· 2011
[cited by applicant]
US 20110152246A1
· Buckman et al.
· 2011
[cited by applicant]
US 20110178117A1
· Converso et al.
· 2011
[cited by applicant]
US 20110218211A1
· Bergeron et al.
· 2011
[cited by applicant]
US 20120030841A1
· Koerber et al.
· 2012
[cited by applicant]
US 20130079342A1
· Dransfield et al.
· 2013
[cited by applicant]
US 20130165440A1
· Anand et al.
· 2013
[cited by applicant]
US 20140107151A1
· Goldstein et al.
· 2014
[cited by applicant]
US 20140194480A1
· Hoppe et al.
· 2014
[cited by applicant]
US 20160194320A1
· Turner et al.
· 2016
[cited by applicant]
US 20160237059A1
· Straub et al.
· 2016
[cited by applicant]
US 20180093956A1
· Dai et al.
· 2018
[cited by applicant]
US 20180215731A1
· Crew et al.
· 2018
[cited by applicant]
US 20200061063A1
· Fürstner et al.
· 2020
[cited by applicant]
US 20210221808A1
· Chen et al.
· 2021
[cited by applicant]
US 20220340567A1
· Dorich et al.
· 2022
[cited by applicant]
US 20230212152A1
· Arnold et al.
· 2023
[cited by applicant]
US 20240158396A1
· Dorich et al.
· 2024
[cited by applicant]
US 20240239808A1
· Berry et al.
· 2024
[cited by applicant]
CL 202203510
· 2023
[cited by applicant]
CL 202302956
· 2024
[cited by applicant]
CL 202400067
· 2024
[cited by applicant]
CN 1984904A
· 2007
[cited by applicant]
CN 103992311A
· 2014
[cited by applicant]
CN 108697709A
· 2018
[cited by applicant]
CN 110563722A
· 2019
[cited by applicant]
CN 111093773A
· 2020
[cited by applicant]
CN 202011562172X
· 2020
[cited by applicant]
CN 2021100906872
· 2021
[cited by applicant]
CN 2021101726650
· 2021
[cited by applicant]
CN 2021105927697
· 2021
[cited by applicant]
CN 2021106294390
· 2021
[cited by applicant]
CN 2021107915923
· 2021
[cited by applicant]
CN 2021108434969
· 2021
[cited by applicant]
CN 2021109400137
· 2021
[cited by applicant]
CN 202110940018X
· 2021
[cited by applicant]
CN 202210015181X
· 2022
[cited by applicant]
CN 2022100156993
· 2022
[cited by applicant]
CN 115417856A
· 2022
[cited by applicant]
CN 116726020A
· 2023
[cited by applicant]
CN 116789674
· 2023
[cited by applicant]
CN 116969920A
· 2023
[cited by applicant]
CN 118056822A
· 2024
[cited by applicant]
EP 0449203A1
· 1991
[cited by applicant]
EP 0623112A1
· 1994
[cited by applicant]
EP 0683212A1
· 1995
[cited by applicant]
EP 0722936A1
· 1996
[cited by applicant]
EP 1451202A1
· 2004
[cited by applicant]
EP 1984353A1
· 2008
[cited by applicant]
EP 1984354A1
· 2008
[cited by applicant]
EP 2285786A1
· 2011
[cited by applicant]
EP 2411379A1
· 2012
[cited by applicant]
EP 2445886A1
· 2012
[cited by applicant]
EP 2459543A1
· 2012
[cited by applicant]
EP 2571876A1
· 2013
[cited by applicant]
EP 2585461A1
· 2013
[cited by applicant]
EP 2621914A1
· 2013
[cited by applicant]
EP 2709983A1
· 2014
[cited by applicant]
EP 2742029A1
· 2014
[cited by applicant]
EP 2847190A1
· 2015
[cited by applicant]
EP 2852572A1
· 2015
[cited by applicant]
EP 2880030A1
· 2015
[cited by applicant]
EP 3045456A1
· 2016
[cited by applicant]
EP 3066100A1
· 2016
[cited by applicant]
EP 3126330A1
· 2017
[cited by applicant]
EP 3237419A1
· 2017
[cited by applicant]
EP 3536685A1
· 2019
[cited by applicant]
EP 3553049A1
· 2019
[cited by applicant]
EP 3604298A1
· 2020
[cited by applicant]
EP 3613751A1
· 2020
[cited by applicant]
GB 1303061A
· 1973
[cited by applicant]
GB 2063249A
· 1981
[cited by applicant]
HK 20098858
· 2024
[cited by applicant]
JP H03284669A
· 1991
[cited by applicant]
JP H06135938A
· 1994
[cited by applicant]
JP 2009120486A
· 2009
[cited by applicant]
WO 1989011279A1
· 1989
[cited by applicant]
WO 1993015058A1
· 1993
[cited by applicant]
WO 1996005176A1
· 1996
[cited by applicant]
WO 1998007430A1
· 1998
[cited by applicant]
WO 2000056719A1
· 2000
[cited by applicant]
WO 2003045967A1
· 2003
[cited by applicant]
WO 2004099158A1
· 2004
[cited by applicant]
WO 2005016000A1
· 2005
[cited by applicant]
WO 2005033288A2
· 2005
[cited by applicant]
WO 2006004589A2
· 2006
[cited by applicant]
WO 2006090273A2
· 2006
[cited by applicant]
WO 2006110516A1
· 2006
[cited by applicant]
WO 2007038367A1
· 2007
[cited by applicant]
WO 2007056184A2
· 2007
[cited by applicant]
WO 2007056281A2
· 2007
[cited by applicant]
WO 2007056580A2
· 2007
[cited by applicant]
WO 2007087276A1
· 2007
[cited by applicant]
WO 2007093402A1
· 2007
[cited by applicant]
WO 2008017161A1
· 2008
[cited by applicant]
WO 2008128968A1
· 2008
[cited by applicant]
WO 2008137084A2
· 2008
[cited by applicant]
WO 2009035568A1
· 2009
[cited by applicant]
WO 2009038812A1
· 2009
[cited by applicant]
WO 2009079008A1
· 2009
[cited by applicant]
WO 2009086303A2
· 2009
[cited by applicant]
WO 2009126947A2
· 2009
[cited by applicant]
WO 2009140163A1
· 2009
[cited by applicant]
WO 2009152909A1
· 2009
[cited by applicant]
WO 2009157386A1
· 2009
[cited by applicant]
WO 2010021934A2
· 2010
[cited by applicant]
WO 2010036544A1
· 2010
[cited by applicant]
WO 2010101949A1
· 2010
[cited by applicant]
WO 2010109005A1
· 2010
[cited by applicant]
WO 2010112545A1
· 2010
[cited by applicant]
WO 2010117935A1
· 2010
[cited by applicant]
WO 2010117936A1
· 2010
[cited by applicant]
WO 2010151791A1
· 2010
[cited by applicant]
WO 2011012883A1
· 2011
[cited by applicant]
WO 2011019780A1
· 2011
[cited by applicant]
WO 2011075607A1
· 2011
[cited by applicant]
WO 2011123751A2
· 2011
[cited by applicant]
WO 2011146358A1
· 2011
[cited by applicant]
WO 2012000595A1
· 2012
[cited by applicant]
WO 2012003264A1
· 2012
[cited by applicant]
WO 2012037132A1
· 2012
[cited by applicant]
WO 2012041814A1
· 2012
[cited by applicant]
WO 2012156400A1
· 2012
[cited by applicant]
WO 2012158810A1
· 2012
[cited by applicant]
WO 2013020622A1
· 2013
[cited by applicant]
WO 2013026939A1
· 2013
[cited by applicant]
WO 2013078254A1
· 2013
[cited by applicant]
WO 2013167495A1
· 2013
[cited by applicant]
WO 2013176698A1
· 2013
[cited by applicant]
WO 2014019344A1
· 2014
[cited by applicant]
WO 2014079935A1
· 2014
[cited by applicant]
WO 2014079941A1
· 2014
[cited by applicant]
WO 2014080291A2
· 2014
[cited by applicant]
WO 2014086737A1
· 2014
[cited by applicant]
WO 2014131315A1
· 2014
[cited by applicant]
WO 2015001348A1
· 2015
[cited by applicant]
WO 2015036560A1
· 2015
[cited by applicant]
WO 2015067549A1
· 2015
[cited by applicant]
WO 2015150995A1
· 2015
[cited by applicant]
WO 2016086200A1
· 2016
[cited by applicant]
WO 2016103037A1
· 2016
[cited by applicant]
WO 2016131098A1
· 2016
[cited by applicant]
WO 2017136871A1
· 2017
[cited by applicant]
WO 2017140778A1
· 2017
[cited by applicant]
WO 2017144341A1
· 2017
[cited by applicant]
WO 2017184604A1
· 2017
[cited by applicant]
WO 2017184623A1
· 2017
[cited by applicant]
WO 2017184624A1
· 2017
[cited by applicant]
WO 2018015445A1
· 2018
[cited by applicant]
WO 2018031680A1
· 2018
[cited by applicant]
WO 2018080216A1
· 2018
[cited by applicant]
WO 2018138050A1
· 2018
[cited by applicant]
WO 2018144649A1
· 2018
[cited by applicant]
WO 2018172925A1
· 2018
[cited by applicant]
WO 2018174678A1
· 2018
[cited by applicant]
WO 2018217651A1
· 2018
[cited by applicant]
WO 2018218071A1
· 2018
[cited by applicant]
WO 2018221433A1
· 2018
[cited by applicant]
WO 2019017741A1
· 2019
[cited by applicant]
WO 2019038215A1
· 2019
[cited by applicant]
WO 2019223548A1
· 2019
[cited by applicant]
WO 2020021015A1
· 2020
[cited by applicant]
WO 2020163248A1
· 2020
[cited by applicant]
WO 2020234715A1
· 2020
[cited by applicant]
WO 2021193897A1
· 2021
[cited by applicant]
WO 2021239885A1
· 2021
[cited by applicant]
WO 2022135567A1
· 2022
[cited by applicant]
WO 2022166890A1
· 2022
[cited by applicant]
WO 2022216971A1
· 2022
[cited by applicant]
WO 2022229315A1
· 2022
[cited by applicant]
WO 2022230912A1
· 2022
[cited by applicant]
WO 2022238347A1
· 2022
[cited by applicant]
WO 2022253326A1
· 2022
[cited by applicant]
WO 2022253936A1
· 2022
[cited by applicant]
WO 2023003002A1
· 2023
[cited by applicant]
WO 2023275366A1
· 2023
[cited by applicant]
WO 2023278438A1
· 2023
[cited by applicant]
WO 2023026222
· 2023
[cited by applicant]
WO 2023028534
· 2023
[cited by applicant]
WO 2023028536
· 2023
[cited by applicant]
WO 2023088856A1
· 2023
[cited by applicant]
WO 2023088987A1
· 2023
[cited by applicant]
WO 2023129987A1
· 2023
[cited by applicant]
WO 2023131277A1
· 2023
[cited by applicant]
WO 2023178099A1
· 2023
[cited by applicant]
WO 2023183943A1
· 2023
[cited by applicant]
WO 2023186020A1
· 2023
[cited by applicant]
WO 2023194964A1
· 2023
[cited by applicant]
WO 2023220408A1
· 2023
[cited by applicant]
WO 2023232917A1
· 2023
[cited by applicant]
WO 2024013395A1
· 2024
[cited by applicant]
WO 2024006559A1
· 2024
[cited by applicant]
WO 2024012551A1
· 2024
[cited by applicant]
WO 2024017924A1
· 2024
[cited by applicant]
WO 2024023266A1
· 2024
[cited by applicant]
WO 2024028782A1
· 2024
[cited by applicant]
WO 2024033845A1
· 2024
[cited by applicant]
WO 2024041460A1
· 2024
[cited by applicant]
WO 2024064245
· 2024
[cited by applicant]
WO 2024090469A1
· 2024
[cited by applicant]
WO 2024094150A1
· 2024
[cited by applicant]
WO 2024094185A1
· 2024
[cited by applicant]
WO 2024097598A1
· 2024
[cited by applicant]
WO 2024099992A1
· 2024
[cited by applicant]
WO 2024099993A1
· 2024
[cited by applicant]
WO 2024099996A1
· 2024
[cited by applicant]
WO 2024109922A1
· 2024
[cited by applicant]
WO 2024121086
· 2024
[cited by applicant]
WO 2024121184
· 2024
[cited by applicant]
WO 2024137319A1
· 2024
[cited by applicant]
WO 2024138045A1
· 2024
[cited by applicant]
WO 2024140704
· 2024
[cited by applicant]
WO 2024140824
· 2024
[cited by applicant]
WO 2024141535A1
· 2024
[cited by applicant]
WO 2024145623A1
· 2024
[cited by applicant]
WO 2024148029A2
· 2024
[cited by applicant]
Database Registry No. RN30181-95-4, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-phenyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 16, 1984; 1 printed page.
[cited by applicant]
Database Registry No. RN296248-99-2, “4-Piperidinol, 1-[3-ethyl-9-[[2-(4-morpholinyl)ethyl]amino]-3Hpyrazolo [4′,3′:5,6]pyrido[3,4-d]pyridazin-6-yl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Oct. 17, 2…
[cited by applicant]
Database Registry No. RN1340993-30-7, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-(3-phenyl-1,2,4-oxadiazol-5-yl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1340906-77-5, “1-Phthalazinamine, 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1340893-35-7, “1-Phthalazinamine, 4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 4, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1217112-04-3, “1-Phthalazinamine, 4-(4-methylphenyl)-N-[2-(4-morpholinyl)ethyl]-, ethanedioate (1:2) (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 6, 2010; 1 printed page.”
[cited by applicant]
Database Registry No. RN1135019-11-2, “1-Phthalazinamine, 4-(3,4-dimethylphenyl)-N-[2-(4-morpholinyl)ethyl]-, ethanedioate (1:2)” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 15, 2009; 1 printed page.
[cited by applicant]
Database Registry No. RN1090983-56-4, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-[2-(4-methoxyphenyl)-2-(4- morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 28, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1090015-30-7, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-[2-methyl-2-(4-morpholinyl)propyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 25, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1078602-84-2, “1-Phthalazinamine, N-[2-(4-morpholinyl)ethyl]-4-phenyl-, ethanedioate (1:1)” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 2, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN1002033-19-3, “1-Phthalazinamine, 4-(4-methylphenyl)-N-[2-(4-morpholinyl)ethyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Feb. 7, 2008; 1 printed page.
[cited by applicant]
Database Registry No. RN 1027552-60-8, “Pyrido[3,4-d]pyridazin-4-amine, 7-(3-methyl-2-pyridinyl)-1-[4-(trifluoromethyl)phenyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Jun. 12, 2008; 3 printed page.
[cited by applicant]
Database Registry No. RN 1018166-04-5, “3-Pyridazinamine, 6-(4-bromophenyl)-N-[(tetrahydro-2-furanyl)methyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 29, 2008; 1 printed page.
[cited by applicant]
Cheung et al. (2018) “Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA)”. Journal of Medicinal Chemistry, 61: 11021-11036.
[cited by applicant]
Kakeya et al., “Studies on Prodrugs of Cephalosporins. I. Synthesis and Biological Properties of Glycyloxybenzoyloxymethyl and Glycylaminobenzoyloxymethyl Esters of 7?-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamid…
[cited by applicant]
Higuchi et al., “Pro-Drugs as Novel Delivery Systems”, A.C.S. Symposium Series, Sep. 1974, vol. 14, pp. 1-245.
[cited by applicant]
Cahn et al., “The Specification of Asymmetric Configuration in Organic Chemistry”, Experientia, 1956, vol. 12, pp. 81-94.
[cited by applicant]
Cahn et al., “Specification of Molecular Chirality”, Angew. Chem. Inter. Edit., 1966, vol. 5, No. 4, pp. 385-415; errata 511.
[cited by applicant]
Cahn et al., “Specification of Configuration about Quadricovalent Asymmetric Atoms”, J. Chem. Soc., Jan. 1951, pp. 612-622.
[cited by applicant]
Bundgaard, H., “Means to Enhance Penetration”, Advanced Drug Delivery Reviews, 1992, vol. 8, pp. 1-38.
[cited by applicant]
Bundgaard, H., “Chapter 5: Design and Application of Pro-drugs”, Drug Design and Development, 1991, pp. 113-191.
[cited by applicant]
Cahn et al., “Specification of molecular chirality”, Angew. Chem., 1966, vol. 78, pp. 413-447.
[cited by applicant]
Widder et al., Methods in Enzymology, 1985, vol. 112, pp. 309-396.
[cited by applicant]
Smith et al., “Chapter 4: Stereochemistry”, March's Advanced Organic Chemistry, 2001, 5th Edition, pp. 125-217.
[cited by applicant]
Alikhan et al., Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. Apr. 2009, 60(4):539-561; quiz 562-563. doi: 10.1016/j.jaad.2008.11.911.
[cited by applicant]
Allen et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. May 10, 2010;207(5):1045-56. doi: 10.1084/jem.20100050. Epub Apr. 12, 2010.
[cited by applicant]
Artlett et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. Nov. 2011;63(11):3563-74. doi: 10.1002/art.30568.
[cited by applicant]
Baldwin et al. Inhibiting the Inflammasome: A Chemical Perspective. J Med Chem. Mar. 10, 2016;59(5):1691-710. doi: 10.1021/acs.jmedchem.5b01091.
[cited by applicant]
Basiorka et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. Dec. 22, 2016; 128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub Oct. 13, 2016.
[cited by applicant]
Braddock et al. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. Apr. 2004;3(4):330-9. doi: 10.1038/nrd1342.
[cited by applicant]
Coll et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. Mar. 2015;21(3):248-55. doi: 10.1038/nm.3806. Epub Feb. 16, 2015.
[cited by applicant]
Cook et al., The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur J Immunol. Mar. 2010;40 (3):631-634. doi: 10.1002/eji.200940162.
[cited by applicant]
Database Registry No. RN 1018067-04-3, “3-Pyridazinamine, 6-(4-chlorophenyl)-N-[(tetrahydro-2-furanyl)methyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Apr. 29, 2008; 1 printed page.
[cited by applicant]
De Nardo et al. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am J Pathol. Jan. 2014;184(1):42-54. doi: 10.1016/j.ajpath.2013.09.007. Epub Oct. 30, 2013.
[cited by applicant]
Dempsey et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-? and cognitive function in APP/PS1 mice. Brain Behav Immun. Mar. 2017;61:306-316. doi: 10.1016/j.bbi.2016.12.014…
[cited by applicant]
Dolunay et al. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-?B, Caspase-1/11, ASC, NOX, and NOS Isoforms. Inflammation. Apr. 2017,40(2):366-386. doi: 10.100…
[cited by applicant]
Doyle et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. May 2012;18(5):791-8. doi: 10.1038/nm.2717.
[cited by applicant]
Duewell et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. Apr. 29, 2010;464(7293):1357-61. doi: 10.1038/nature08938. Erratum in: Nature. Jul. 29, 2010;466(7306):652.
[cited by applicant]
Fang et al. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. J Dermatol Sci. Aug. 2016;83(2):116-23. doi: 10.1016/j.jdermsci.2016.04.009. Epub Apr. 29, 2016.
[cited by applicant]
Feng et al., The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res. Jun. 21, 2017;36(1):81. doi: 10.1186/s13046-017-0553-x.
[cited by applicant]
Granata et al., NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. PLoS One. Mar. 23, 2015;10(3):e0122272. doi: 10.1371/journal.pone.0122272.
[cited by applicant]
Gugliandolo et al. NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model. Inflammation. Feb. 2018;41(1):93-103. doi: 10.1007/s10753-017-0667-5.
[cited by applicant]
Henao-Meija et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. Feb. 1, 2012;482(7384):179-85. doi: 10.1038/nature 10809.
[cited by applicant]
Hu et al. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A. Jan. 26, 2010;107(4):1506-11. doi: 10.1073/pnas.0907763107. Epub Jan. 4, 2010.
[cited by applicant]
Huang et al., NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma. J Exp Clin Cancer Res. Sep. 2, 2017;36(1):116. doi: 10.1186/s13046-017-0589-y.
[cited by applicant]
Iannitti et al., IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun. Mar. 14, 2016;7:10791. doi: 10.1038/ncomms10791.
[cited by applicant]
Inoue et al. The role of interferon-? in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis—in the perspective of inflammasomes. Immunology. May 2013;139(1):11-8. doi: 10.1111/mm.12081.
[cited by applicant]
Ismael et al., MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury. J Neurotrauma. Jun. 1, 2018;35(11):1294-1303. doi: …
[cited by applicant]
Jager et al., D38 Flying: Reaching New Heights in Sarcoidosis: Key Role of Nirp3 Inflammasome Activation In Granuloma Generation of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine 191 (2015): 1 p…
[cited by applicant]
Jia et al. Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain. Mol Pain. Jan.-Dec. 2017; 13:1744806917719804. doi: 10.1177/1744806917719804.
[cited by applicant]
Kaizerman et al. Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel byridopyridazines. Bioorg Med Chem Lett. Aug. 1, 2010;20(15):4607-10. doi: 10.1016/j.bmcl.2010.06.006. Epub Ju…
[cited by applicant]
Kim et al. Role for NLRP3 Inflammasome-mediated, IL-1?-Dependent Responses in Severe, Steroid-Resistant Asthma. Am J Respir Crit Care Med. Aug. 1, 2017;196(3):283-297. doi: 10.1164/rccm.201609-18300C.
[cited by applicant]
Lazaridis et al. Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis. Dig Dis Sci. Sep. 2017; 62(9):2348-2356. doi: 10.1007/s10620-017-4609-8. Epub …
[cited by applicant]
Li et al. (2016) Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma, Hematology, 21:3, 144-151, DOI: 10.1179/1607845415Y.0000000029.
[cited by applicant]
Li et al. Aging-related gene signature regulated by Nlrp3 predicts glioma progression. Am J Cancer Res. 2015;5 (1):442-9.
[cited by applicant]
Loukovaara et al. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol. Dec. 2017;95(8):803-808. doi: 10.1111/aos.13427. Epub Mar. 8, 2017.
[cited by applicant]
Lu et al. Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus. J Immunol. Feb. 1, 2017; 198(3):1119-1129; DOI: https://doi.org/10.4049/jimmunol.1600659.
[cited by applicant]
Masters, Specific inflammasomes in complex diseases. Clin Immunol. Jun. 2013;147(3):223-228. doi: 10.1016/j.clim.2012.12.006.
[cited by applicant]
Menu et al. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. Oct. 2011; 166(1):1-15. doi: 10.1111/j.1365-2249.2011.04440.x. Epub Jul. 15, 2011.
[cited by applicant]
Mridha et al., NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. May 2017;66(5):1037-1046. doi: 10.1016/j.jhep.2017.01.022.
[cited by applicant]
Neudecker et al., Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 Inflammasome. J Exp Med. Jun. 5, 2017;214(6):1737-1752. doi: 10.1084/jem.20160462.
[cited by applicant]
Niebuhr et al., Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu. Allergy. Aug. 2014;69(8):1058-1067. doi: 10.1111/all.12428.
[cited by applicant]
Ozaki et al., Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res. Jan. 16, 2015;8:15-27. doi: 10.2147/JIR.S51250.
[cited by applicant]
Perregaux et al.; Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther. Oct. 2001;299(1):187-197.
[cited by applicant]
Primiano et al., Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation. J Immunol. Sep. 15, 2016;197(6):2421-2433. doi: 10.4049/immunol.16…
[cited by applicant]
Puyang et al., Retinal Ganglion Cell Loss is Delayed Following Optic Nerve Crush in NLRP3 Knockout Mice. Sci Rep. Feb. 19, 2016;6:20998. doi: 10.1038/srep20998.
[cited by applicant]
Qin et al., Propionibacterium acnes induces IL-1? secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol. Feb. 2014;134(2):381-388. doi: 10.1038/jid.2013.309.
[cited by applicant]
Ridker et al., CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. Sep. 21, 2017;377(12):1119-1131. doi: 10.1056/NEJMoa1707914.
[cited by applicant]
Ridker et al., CANTOS Trial Group. Effect of interleukin-1? inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled t…
[cited by applicant]
Sano et al., Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1?/NLRP3 Inflammasome. J Am Coll Cardiol. Feb. 27, 2018;71(8):875-886. doi: 10.1016/j.jacc.2017.12.037.
[cited by applicant]
Schroder et al., The inflammasomes. Cell. Mar. 19, 2010;140(6):821-832. doi: 10.1016/j.cell.2010.01.040.
[cited by applicant]
Schroder et al., The NLRP3 inflammasome: a sensor for metabolic danger? Science. Jan. 15, 2010;327(5963):296-300. doi: 10.1126/science. 1184003.
[cited by applicant]
Scott et al., A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. Jan.-Feb. 201634(1):88-93.
[cited by applicant]
Behalo et al., “Synthesis of Novel Phthalazine Derivatives as Potential Anticancer and Antioxidant Agents Based on 1-Chloro-4-(4-phenoxyphenyl)phthalazine”, J Heterocyclic Chem, Sep. 2017, vol. 54, No. 6, pp. 3591-3599.
[cited by applicant]
Colotta, et al., “Synthesis and structure-activity relationships of 1-aminophthalazinium salts as GABAA receptor antagonists”, European Journal of Medicinal Chemistry, 1994, vol. 29, No. 2, pp. 95-105.
[cited by applicant]
Johnsen et al., “New antithrombotic 1-Phthalazinamines with Serotonin Antagonistic Properties”, Arch. Pharm, Dec. 2003, vol. 336, No. 12, pp. 591-597.
[cited by applicant]
Sayed et al., “Synthesis and reactions of 4-aryl-1(2H) phthalazinones”, Chinese Journal of Chemistry, Jan. 1991, vol. 9, No. 1, pp. 45-53.
[cited by applicant]
U.S. Appl. No. 17/984,018, filed Nov. 9, 2022.
[cited by applicant]
Kassab (2005). Synthesis and behaviour of 4-[4?-chloro-3?-methyl phenyl]-1 [2H]-phthalazinone towards certain electrophiles and nucleophiles. Egyptian Journal of Chemistry, 48(2), 183-199.
[cited by applicant]
Database Registry No. RN1181498-12-3, “Benzamide, 4-[4-(cyclopentylamino)-1-phthalazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 9, 2009; 1 printed page.
[cited by applicant]
Database Registry No. RN1267866-53-4, “1-Phthalazinamine, 4-(4-fluorophenyl)-N-3-pyrrolidinyl-”(CA Index Name). STN, Chemical Abstracts Service; entered Mar. 10, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1310214-26-6, “1-Phthalazinamine, 4-(4-methylphenyl)-N-3-pyrrolidinyl-”CA Index Name). STN, Chemical Abstracts Service; entered Jun. 23, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN2198981-59-6, “Cyclopentanecarboxylic acid, 3-hydroxy-4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]-” (CA Index Name). STN, Chemical Abstracts Service; Mar. 26, 2018; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-57-1, “1-Phthalazinamine, N-cyclohexyl-4-(3,4-dimethylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-58-2, “1-Phthalazinamine, N-cyclohexyl-4-(4-methylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-60-6, “1-Phthalazinamine, N-cyclohexyl-4-(2,4-dimethylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-62-8, “1-Phthalazinamine, N-cyclohexyl-4-(2,5-dimethylphenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-63-9, “1-Phthalazinamine, N-cyclohexyl-4-(4-fluorophenyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN447430-65-1, “1-Phthalazinamine, 4-(4-chlorophenyl)-N-cyclohexyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Sep. 6, 2002; 1 printed page.
[cited by applicant]
Database Registry No. RN694474-51-6 “Phthalazine, 1-(cyclohexyloxy)-4-(4-methylphenyl)-”(CA Index Name). STN, Chemical Abstracts Service; entered Jun. 17, 2004; 1 printed page.
[cited by applicant]
Database Registry No. RN852664-73-4, “1-Phthalazinamine, N-cycloheptyl-4-(4-methylphenyl)-”(CA Index Name). STN, Chemical Abstracts Service; entered Jun. 22, 2005; 1 printed page.
[cited by applicant]
Database Registry No. RN1351271-90-3, “3-Pyridazinamine, N-(1-methylethyl)-6-(1,2,3,4-tetrahydro-5-isoquinolinyl)-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 19, 2011; 1 printed page.
[cited by applicant]
Database Registry No. RN1482843-77-5, “1-Naphthalenol, 2-[6-(propylamino)-3-pyridazinyl]-” (CA Index Name). STN, Chemical Abstracts Service; entered Nov. 28, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1485079-65-9, “1-Naphthalenol, 2-[6-(ethylamino)-3-pyridazinyl]-”(CA Index Name). STN, Chemical Abstracts Service; entered Dec. 2, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1488322-94-6, “1-Phthalazinamine, 4-(2-methoxyphenyl)-N-methyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 5, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1494117-54-2, “1-Phthalazinamine, 4-(2-methoxy-5-methylphenyl)-N-methyl-” (CA Index Name). STN, Chemical Abstracts Service; entered Dec. 13, 2013; 1 printed page.
[cited by applicant]
Database Registry No. RN1496330-00-7, “1-Phthalazinamine, 4-(5-fluoro-2-methoxyphenyl)-N-methyl-”(CA Index Name). STN, Chemical Abstracts Service; entered Dec. 16, 2013; 1 printed page.
[cited by applicant]